The protocols offer a more accurate way to detect atherosclerosis and assess cardiovascular risk before symptoms appear, ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis - a primary driver of ...

Atherosclerosis is a chronic ... 2019;8a] Less common manifestations of ASCVD affect the thoracic or abdominal aorta, the renal arteries or the mesenteric arteries. [Libby P, et al.

Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis — a primary driver of cardiovascular death worldwide — in large mammals, a study suggests.

Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) ...

Many causes exist including atherosclerosis ... and can visualized the entire thoracic aorta. This is the preferred method if chronic kidney disease prohibits the use of contrast imaging with ...

Transscatheter aortic valve replacement is a novel ... to document the extent of atherosclerotic disease in the peripheral vasculature. The transfemoral approach is the preferred route for TAVR ...